Key result
Adipokines released from adipose tissue mediate the pathogenesis of obesity-related metabolic disturbances and atherosclerosis, representing a potential target for new treatment strategies.
This review highlights the role of adipokines as active endocrine mediators linking obesity to atherosclerosis, presenting them as potential novel therapeutic targets.
May support adipokine-targeted therapies in obesity-related atherosclerosis; leaves open validation in prospective trials.
The traditional perception of adipose tissue as a storage organ of fatty acids has been replaced by the notion that adipose tissue is an active endocrine organ, releasing various adipokines that are involved in the pathogenesis of obesity-related metabolic disturbances. Obesity is a well-known risk factor for atherosclerosis, and accelerates atherosclerosis by many mechanisms such as increase in blood pressure and glucose level, abnormal lipid profiles, and systemic inflammation. Furthermore, growing evidence suggests that some adipokines directly mediate the process of atherosclerosis by influencing the function of endothelial cells, arterial smooth muscle cells, and macrophages in vessel walls. In obese patients, the secretion and coordination of such adipokines is abnormal, and the secretion of specific adipokines increases or decreases. Accordingly, the discovery of new adipokines and elucidation of their functions might lead to a new treatment strategy for metabolic disorders related to obesity, including cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Hye Jin Yoo (2014) conducted a review in Obesity and atherosclerosis. Adipokines was evaluated. Adipokines released from adipose tissue mediate the pathogenesis of obesity-related metabolic disturbances and atherosclerosis, representing a potential target for new treatment strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: